Table 1.
Single score and sum of scores of the 15 panelists for structured report in the first round
| Panelist # | A1. Anthropometric data | A2. Personal assessments | A3. Allergies and adverse reactions | B1. Clinical information | C1. Examination data | C2. Contrast agent | C3. Study protocol | C4. Adverse Events | D1.Lesion | D2. Lymphadenopathy | D3. Distant metastasis | D4. Carcinosis | D5. Free payment | D6. Perforation | D7. TNM stage | D8. Accessory findings | Tot |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 5 | 3 | 3 | 5 | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 5 | 5 | 4 | 5 | 74 |
| 2 | 2 | 2 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 3 | 72 |
| 3 | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 79 |
| 4 | 5 | 3 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 5 | 4 | 5 | 5 | 5 | 5 | 5 | 76 |
| 5 | 3 | 1 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 74 |
| 6 | 3 | 1 | 4 | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 2 | 3 | 67 |
| 7 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 79 |
| 8 | 5 | 5 | 5 | 4 | 4 | 4 | 4 | 4 | 5 | 4 | 5 | 4 | 5 | 5 | 5 | 4 | 72 |
| 9 | 3 | 3 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 5 | 75 |
| 10 | 1 | 4 | 1 | 3 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 69 |
| 11 | 3 | 4 | 4 | 4 | 5 | 5 | 3 | 5 | 2 | 3 | 3 | 5 | 5 | 3 | 5 | 5 | 64 |
| 12 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 80 |
| 13 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 80 |
| 14 | 5 | 5 | 5 | 5 | 5 | 5 | 3 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 78 |
| 15 | 4 | 3 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 5 | 1 | 72 |
| Mean | 3.93 | 3.60 | 4.47 | 4.73 | 4.87 | 4.93 | 4.60 | 4.93 | 4.67 | 4.80 | 4.80 | 4.93 | 5.00 | 4.73 | 4.67 | 4.40 | 74.07 |
| Std | 1.33 | 1.45 | 1.13 | 0.59 | 0.35 | 0.26 | 0.74 | 0.26 | 0.82 | 0.56 | 0.56 | 0.26 | 0.00 | 0.59 | 0.82 | 1.18 | 4.85 |